|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Net product sales | |||||
| Grant revenue | |||||
| Other revenue | |||||
| Total revenue | |||||
| Operating expenses: | |||||
| Cost of sales | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Interest income | |||||
| Other expense, net | |||||
| Loss before income taxes | |||||
| Provision for (benefit from) tax provision | |||||
| Net loss | |||||
| Net loss per share | |||||
| Basic (in usd per share) | |||||
| Diluted (in usd per share) | |||||
| Weighted average common shares used in calculation of loss per share: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...
